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Abstract
Objectives: Real-world experience from a 6-month product familiarization programme (PFP) for 3-monthly
paliperidone palmitate in schizophrenia maintenance treatment.
Methods: Prescribers completed an online questionnaire for each patient at enrolment with further questions
at second dose (re-supply) stage and a second survey of their overall experience at the end.
Results: Ninety-four patients were enrolled and received a first dose and 23 received a second dose within the
6-month programme; 51.1% had been hospitalised for symptom relapse in the previous 2 years. Reasons for
prescribing were convenience of 3-monthly dosing for patients (94.7%) and patient choice (54.6%).
Prescribers followed-up at least once-monthly (69.6% cases) and indicated in 48.9% they would consider
shared GP care. All patients were satisfied with symptom control and either maintained functioning or
showed improvement. Clinicians felt confident with administration and identifying suitable patients and were
all 'satisfied' or 'somewhat satisfied' with efficacy and tolerability. All felt patients' treatment goals were either
'met' (81.3%) or 'partly met' (18.7%) and none reported dissatisfaction with relapse prevention.
Conclusions: Convenient 3-monthly dosing was preferred by clinicians and patients, and symptoms were
adequately managed. This has the potential to improve adherence and lead to better outcomes as patients only
need four intramuscular doses per year.
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We report on real-world experience with 3-monthly paliperidone palmitate (INVEGA TRINZA®) from a 6-month Australian product 
familiarization programme (PFP). PFPs allow the medical 
profession to evaluate and become familiar with a prod-
uct.1 Three-monthly paliperidone palmitate is an inject-
able antipsychotic agent for the maintenance treatment 
of schizophrenia in adult patients previously main-
tained with 1-monthly paliperidone palmitate (INVEGA 
SUSTENNA®) for at least 4 months.2 Treatment was in 
line with the approved indication and the Australian 
Approved Product Information.1,2
Antipsychotic medications are the cornerstone of effec-
tive management of schizophrenia but treatment conti-
nuity is critical, as discontinuation even for short 
periods can lead to poorer outcomes.3 Non-adherence 
remains a major problem, leading to a relapse of psy-
chotic symptoms and deterioration of functioning.4,5 
Relapse is associated with poorer long-term outcomes, 
inability to work, psychiatric re-hospitalisation, com-
mitting or being a victim of crime, self-harm, substance 
abuse and suicide.5 However, better antipsychotic 
adherence leads to improved quality of life, and preven-
tion of relapse is a key aspect of current schizophrenia 
management guidelines.3,5
Long-acting injectable antipsychotic agents have 
improved adherence compared to oral formulations, by 
simplifying dosing and reducing relapse.5 Patients do 
not need to remember to take drugs daily and greater 
transparency means that healthcare professionals can be 
Early Australian experience in the 
maintenance of schizophrenia 
management with 3-monthly 
paliperidone palmitate
Nagesh Pai Foundation Professor of Psychiatry, Graduate Medicine, Faculty of Science, Health and Medicine, University of 
Wollongong, Wollongong, NSW, Australia
Matthew Warden Director AIS, St Vincent’s Hospital, Melbourne, VIC, Australia
Abstract
Objectives: Real-world experience from a 6-month product familiarization programme (PFP) for 3-monthly paliperi-
done palmitate in schizophrenia maintenance treatment.
Methods: Prescribers completed an online questionnaire for each patient at enrolment with further questions at 
second dose (re-supply) stage and a second survey of their overall experience at the end.
Results: Ninety-four patients were enrolled and received a first dose and 23 received a second dose within the 
6-month programme; 51.1% had been hospitalised for symptom relapse in the previous 2 years. Reasons for prescrib-
ing were convenience of 3-monthly dosing for patients (94.7%) and patient choice (54.6%). Prescribers followed-
up at least once-monthly (69.6% cases) and indicated in 48.9% they would consider shared GP care. All patients 
were satisfied with symptom control and either maintained functioning or showed improvement. Clinicians felt 
confident with administration and identifying suitable patients and were all ‘satisfied’ or ‘somewhat satisfied’ with 
efficacy and tolerability. All felt patients’ treatment goals were either ‘met’ (81.3%) or ‘partly met’ (18.7%) and none 
reported dissatisfaction with relapse prevention.
Conclusions: Convenient 3-monthly dosing was preferred by clinicians and patients, and symptoms were ade-
quately managed. This has the potential to improve adherence and lead to better outcomes as patients only need 
four intramuscular doses per year.
Keywords: schizophrenia, long-acting antipsychotic agents, survey, maintenance therapy, relapse
Corresponding author:
Nagesh B Pai, Faculty of Science, Health and Medicine, 
University of Wollongong, Wollongong, NSW 2522, Australia. 
Email: nagesh@uow.edu.au
789770 APY Australasian PsychiatryPai and Warden
Pharmacotherapy
Pai and Warden
629
alerted and intervene quickly if patients miss their med-
ication. Plasma levels also decrease more slowly with 
long-acting injectable formulations, reducing the poten-
tial speed of a relapse occurring, which also allows earlier 
intervention.5–7 Less frequent injections allows more 
time for patients and physicians to address other impor-
tant treatment objectives such as psychosocial issues, 
substance abuse, smoking cessation, health mainte-
nance, and vocational rehabilitation.8
Paliperidone palmitate (INVEGA TRINZA®) is currently 
the only 3-monthly antipsychotic formulation approved 
for the treatment of schizophrenia.9 In Phase 3 clinical 
trials, 3-monthly paliperidone palmitate was more effec-
tive than placebo in delaying time to relapse and reduc-
ing relapse rates. It was non-inferior to 1-monthly 
paliperidone palmitate in the proportion of patients that 
remained relapse-free. Its side-effect profile was similar 
to 1-monthly paliperidone palmitate and was well toler-
ated with no new safety concerns.10,11 Prior to its 
approval, long-acting antipsychotics were only available 
in 2-weekly or 4-weekly formulations.9
Methods
The PFP ran for 6 months and included 94 patients, 
enrolled by 16 prescribing clinicians in six states across 
Australia. All patients needed to be adequately main-
tained on 1-monthly paliperidone palmitate for at least 
4 months prior to starting 3-monthly paliperidone pal-
mitate. At enrolment, clinicians completed a prelimi-
nary online questionnaire for each patient supply 
request (Table 1). When requesting re-supply (a second 
dose) they were prompted to answer additional follow-
up questions regarding their perception of the patient’s 
experience. A total of 23 patients (25%) received a sec-
ond dose before the programme ended. At the end of the 
PFP, each prescriber completed a second survey on their 
overall experience (Table 2).
No formal protocol was required under Medicines 
Australia guidance for the conduct of a PFP, as individual 
patient data was not collected, only aggregated data on 
the prescriber’s experience with the product.1
Results
Patient characteristics
Of the 94 patients enrolled, 75.5% identified as male 
and 24.5% female. Participants were aged from 20 to 
73 years old (median 43.5 years) and age at diagnosis var-
ied from 14 to 63 years old.
The majority of patients (77.7%) had been maintained 
on the higher doses of 1-monthly paliperidone palmi-
tate, 100 mg (39.4%), and 150 mg (38.3%). The length of 
maintenance on 1-monthly paliperidone palmitate var-
ied from the minimum of 4 months to 98 months (mean 
28.6 ± 20.1 months); 51.1% of patients had been hospi-
talised due to symptom relapse in the previous 2 years 
prior to enrolment.
Patient experience (clinician-reported)
The most prevalent reason for prescribing 3-monthly pali-
peridone palmitate (94.7%) was ‘convenience of 3-monthly 
dosing for the patient’. In 56.4% of cases the patient chose 
or requested 3-monthly paliperidone palmitate. In 43.6% 
the prescriber cited their own preference, and in 21.3% of 
cases prior poor medication adherence was a factor.
For the majority of patients (68.1%), clinicians reported 
planned follow-up care at least once-monthly and this 
figure remained similar (69.6%) when asked again at the 
re-supply stage. In 48.9% of cases, clinicians said they 
would consider shared care with a GP.
For all patients at the re-supply stage, clinicians reported 
that functioning was maintained or in 13.1% of cases 
functioning was improved. All patients were satisfied 
(‘somewhat satisfied’, ‘very satisfied’ or ‘completely sat-
isfied’) with the control of their symptoms (Table 3).
Prescriber experience
All clinicians felt confident with the administration of 
3-monthly paliperidone palmitate and in identifying 
suitable patients for treatment. They were all either ‘sat-
isfied’ (81%) or ‘somewhat satisfied’ (19%) with efficacy 
and tolerability. No one reported dissatisfaction with 
relapse prevention and all felt that the treatment goal 
for their patients was either ‘met’ (81.3%) or ‘partly met’ 
(18.7%) whilst on 3-monthly paliperidone palmitate. All 
participants reported being either ‘satisfied’ (62.5%) or 
‘somewhat satisfied’ (37.5%) with the PFP itself (Table 4).
Discussion and conclusions
The results of these real-world experience surveys indi-
cate a high level of satisfaction and confidence with 
3-monthly paliperidone palmitate, as reported by pre-
scribers. Collectively, prescribers felt their patients’ treat-
ment goal was met in most cases, patient functioning 
was maintained or improved in every case, and patients 
appeared satisfied with symptom control. There were no 
major relapses or readmissions to hospital, which would 
allow more opportunity to devote the time needed for 
psychosocial and other aspects of patient recovery.
It is anticipated that 3-monthly paliperidone palmitate 
will play a significant role in maintenance treatment for 
schizophrenia patients by delaying time to relapse and 
reducing non-adherence, with the potential to improve 
clinical outcomes and reduce the burden on the health-
care system.7,12 It requires less frequent dosing than 
other currently available antipsychotic agents, as 
patients only need four injections per year compared to 
12 monthly injections or 24 fortnightly injections.2 This 
is could benefit not only stable, high-functioning 
patients who are likely to find the 3-monthly dosing 
schedule more user-friendly but an important group 
who, for logistical, financial, or psychosocial reasons, 
struggle to access appropriate healthcare and maintain 
treatment.
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Table 1. PFP preliminary survey questions. Prescribers answered questions for each patient at enrolment with 
further questions when they ordered their second dose
PFP survey questions at enrolment
Patient initials
Patient year of birth
Patient’s gender
State/Territory where the patient resides
Patient’s age at diagnosis
In the past 2 years, how many hospitalisations due to relapse of schizophrenia symptoms has the patient had?
How long has the patient been maintained on INVEGA SUSTENNA®?
Patient’s anticipated start date on INVEGA TRINZA®
What medication did the patient use immediately prior to treatment with INVEGA SUSTENNA® (paliperidone palmitate 
injectable)?
<Please choose one>
  •  Aripiprazole
  •  Asenapine
  •  Clozapine
  •  Flupenthixol decanoate
  •  Fluphenazine decanoate
  •  Haloperidol decanoate
  •  Lurasidone
  •  Olanzapine
  •  Paliperidone palmitate (oral)
  •  Quetiapine
  •  Risperidone
  •  Ziprasidone
  •  Zuclopenthixol decanoate
  •  Other (Please specify)
What was the patient’s last INVEGA SUSTENNA® dose? (Prior to initiation on INVEGA TRINZA®)
<Please select one >
  •  50 mg
  •  75 mg
  •  100 mg
  •  150 mg
Where was INVEGA SUSTENNA® administered?
<Please select one >
  •  Deltoid
  •  Gluteal
Where will the first dose of INVEGA TRINZA® be administered? <Please select one >
  •  Deltoid
  •  Gluteal
Why have you prescribed INVEGA TRINZA® to this patient?
<You can select more than one>
  •  The convenience of the 3 monthly administration to you
  •  The convenience of the 3 monthly dosing for the patient
  •  Patient choice/request
  •  Prior poor medication adherence
  •  Other (please specify)
(Continued)
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PFP survey questions at enrolment
After initiation on INVEGA TRINZA®, what is your preference for frequency of follow-up (from you as prescribing physician) 
before the next dose?
<Please select one >
  •  Won’t be providing ongoing care
  •  Every 2 weeks
  •  Every month
  •  Every 2 months
  •  At next dose (3 months)
After initiation of INVEGA TRINZA®, how soon would you consider shared care with a GP?
<Please select one >
  •  I would not consider shared care with a GP
  •  After dose 1
  •  After dose 2
  •  After dose 3
QUESTIONS AT RE-ORDER STAGE (SECOND DOSE)
In which setting will the second dose of INVEGA TRINZA® be administered?
<Please select one >
  •  Community mental health centre
  •  Primary care
  •  Private clinic
  •  Hospital
  •  Other
3 months after initiation of INVEGA TRINZA®, what is your preference for frequency of follow-up (from you as prescribing 
physician) for ongoing management?
<Please select one >
  •  Won’t be providing on-going care
  •  Every 2 weeks
  •  Every month
  •  Every 2 months
  •  At next dose (3 months)
How satisfied are your patients with the ongoing control of their symptoms with INVEGA TRINZA®?
<Please select one >
  •  Not at all satisfied
  •  Slightly satisfied
  •  Somewhat satisfied
  •  Very satisfied
  •  Completely satisfied
Please select as appropriate. Following administration of the first dose the patient has:
  •  Not maintained his/her functioning
  •  Maintained his/her functioning
  •  Slightly improved his/her functioning
  •  Significantly improved his/her functioning
Table 1. (Continued)
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Table 2. End of PFP survey questions. Each prescriber answered these questions at the end of the programme 
regarding their own experience
SURVEY QUESTIONS
How confident were you in identifying whether a patient was suitable for INVEGA TRINZA® use?
<Please select one>
  •  Completely confident
  •  Very Confident
  •  Confident
  •  Slightly confident
  •  Not at all confident
How confident are you with the administration of INVEGA TRINZA®? <Please select one >
  •  Completely confident
  •  Very Confident
  •  Confident
  •  Slightly confident
  •  Not at all confident
How satisfied are you with the effectiveness (efficacy and tolerability) of INVEGA TRINZA®?
<Please select one>
  •  Very satisfied
  •  Somewhat satisfied
  •  Neither satisfied nor dissatisfied
  •  Somewhat dissatisfied
  •  Very dissatisfied
How satisfied are you with relapse prevention (reduced risk of rehospitalisation) with INVEGA TRINZA®? <Please select one>
  •  Very satisfied
  •  Somewhat satisfied
  •  Neither satisfied nor dissatisfied
  •  Somewhat dissatisfied
  •  Very dissatisfied
Collectively, was your treatment goal for the patients met during this programme? <Please select one>
  •  Met
  •  Partially met
  •  Not met
How comfortable are you with patient management, given the longer dosing interval of INVEGA TRINZA®? <Please select 
one>
  •  Very comfortable
  •  Somewhat comfortable
  •  Neither comfortable nor uncomfortable
  •  Somewhat uncomfortable
  •  Very uncomfortable
Overall satisfaction: On a scale of 1 to 10, how likely are you to recommend INVEGA TRINZA® to a colleague for use in their 
patients? <Please provide a rating between 1 and 10 (1 not at all likely to 10 extremely likely)
Please rate your level of satisfaction with the INVEGA TRINZA® Product Familiarisation Program?
<Please select one >
  •  Very satisfied
  •  Somewhat satisfied
  •  Neither satisfied nor dissatisfied
  •  Somewhat dissatisfied
  •  Very dissatisfied
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When choosing an antipsychotic, shared decision-making 
that considers patient preference and choice is important.3 
In other surveys from the Phase 3 clinical trials of 3-monthly 
paliperidone palmitate, both patients and physicians pre-
ferred long-acting injectables over oral formulations, and 
physicians showed a greater preference for 3-monthly ver-
sus 1-monthly dosing.13 The findings of this Australian PFP 
confirmed that these were also significant factors when 
prescribing this medication within this setting.
A significant number of specialists indicated a willingness 
to share patient management with GPs. For patients who 
are stable and well controlled, this would reduce costs and 
increase convenience as the number of specialist visits 
Table 3. PFP primary survey: patient response at second dose stage (n = 23)
Completely 
satisfied
Very  
satisfied
Somewhat 
satisfied
Slightly 
satisfied
Not  
satisfied
Do patients appear satisfied with 
ongoing symptom control after first 
dose?
4.5% 81.9% 13.6% 0 0
 Significantly 
improved func-
tioning
Slightly
improved  
functioning
Maintained 
functioning
Not  
maintained 
functioning
NA
Patient functioning after first dose 0 13.6% 86.4% 0 NA
Table 4. End of PFP survey responses: prescriber satisfaction, comfort and confidence (n = 16)
Very  
satisfied
Somewhat 
satisfied
Neither satisfied 
nor dissatisfied
Somewhat 
dissatisfied
Very  
dissatisfied
Satisfaction with relapse prevention 56.25% 37.5% 6.25% 0 0
Satisfaction with effectiveness 81.25% 18.75% 0 0 0
Satisfaction with PFP 62.5% 37.5% 0 0 0
 Completely 
confident
Very  
confident
Confident Slightly  
confident
Not at all 
confident
Confidence in identifying suitable 
patients
18.75% 69.75% 12.5% 0 0
Confidence with product 
administration
18.75% 62.5% 12.5% 6.25% 0
 Very  
comfortable
Somewhat 
comfortable
Neither  
comfortable nor 
uncomfortable
Somewhat 
uncomfortable
Very  
uncomfortable
Comfort with patient management 62.5% 37.5% 0 0 0
 Met Partially
met
Not met NA NA
Was treatment goal met? 81.25% 18.75% 0 NA NA
 1–6 7 8 9 10
Overall satisfaction: Likely to 
recommend to a colleague
(Rating: 1 - not at all likely, 10 - 
extremely likely)
0 6.25% 37.5% 31.25% 25.0%
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could be reduced. However, 3-monthly dosing should not 
be the only reason for less frequent follow-up. Patients 
should still continue to see a mental healthcare profes-
sional as often as required, based on the management 
needs of the individual patient.3 Given that treatment 
will be lifelong, it is highly likely that patients will even-
tually transition to their GP for ongoing care.
It is important to select the right patients for this treat-
ment and prescribers reported that they felt confident 
with this. Those already adequately maintained on the 
1-monthly formulation may be less likely to have previ-
ously unknown side-effect issues. There was no new or 
increased severity of side effects, compared to 1-monthly 
preparations.10 Maintaining a regular follow-up schedule 
would also ensure that any adverse effects are identified 
and managed early.3 Acute side effects are expected to be 
less of a problem where patients have already been ade-
quately maintained on other paliperidone formulations.14
As the enrolment period for PFPs may not exceed 6 months, 
the majority (75%) of patients only received one dose of 
3-monthly paliperidone palmitate during the time frame 
allowed.1 PFP guidelines also place limits on the data that 
can be collected and only aggregated patient data could be 
used in this study.1 However, these data have been collected 
from the use of this medicine outside the constraints of 
randomised controlled trial conditions. Such real-world 
evidence is increasingly being recognised as a valuable asset 
in clinical decision making.15 These findings, taken together 
with the available evidence base, suggest that 3-monthly 
paliperidone palmitate has the potential to improve adher-
ence and clinical outcomes for schizophrenia patients.
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